IRIS
MATERA, Maria Gabriella
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 18.056
NA - Nord America 8.749
AS - Asia 8.123
SA - Sud America 1.500
AF - Africa 99
Continente sconosciuto - Info sul continente non disponibili 13
OC - Oceania 11
Totale 36.551
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 11.364
US - Stati Uniti d'America 8.634
SG - Singapore 3.219
IE - Irlanda 1.953
CN - Cina 1.545
HK - Hong Kong 1.514
BR - Brasile 1.281
UA - Ucraina 1.117
GB - Regno Unito 884
IT - Italia 862
VN - Vietnam 843
DE - Germania 754
FI - Finlandia 288
KR - Corea 267
FR - Francia 260
GR - Grecia 220
SE - Svezia 191
TR - Turchia 183
IN - India 180
JP - Giappone 92
AR - Argentina 77
MX - Messico 45
ID - Indonesia 43
BD - Bangladesh 41
CA - Canada 38
IQ - Iraq 37
EC - Ecuador 34
BE - Belgio 25
CO - Colombia 25
NL - Olanda 24
ZA - Sudafrica 23
CL - Cile 22
ES - Italia 20
UZ - Uzbekistan 20
PK - Pakistan 19
MA - Marocco 18
PY - Paraguay 18
VE - Venezuela 18
AT - Austria 17
PE - Perù 16
PL - Polonia 15
DZ - Algeria 13
IL - Israele 13
EG - Egitto 10
MD - Moldavia 10
MY - Malesia 10
TW - Taiwan 10
AE - Emirati Arabi Uniti 8
AU - Australia 8
EU - Europa 8
IR - Iran 8
TH - Thailandia 8
TN - Tunisia 8
BG - Bulgaria 7
DO - Repubblica Dominicana 7
ET - Etiopia 7
KE - Kenya 7
SA - Arabia Saudita 7
AL - Albania 6
CZ - Repubblica Ceca 6
JM - Giamaica 6
NP - Nepal 6
PH - Filippine 6
BB - Barbados 5
CH - Svizzera 5
CI - Costa d'Avorio 5
LB - Libano 5
AZ - Azerbaigian 4
HN - Honduras 4
OM - Oman 4
UY - Uruguay 4
BH - Bahrain 3
BO - Bolivia 3
BY - Bielorussia 3
JO - Giordania 3
KG - Kirghizistan 3
KZ - Kazakistan 3
LT - Lituania 3
NZ - Nuova Zelanda 3
PS - Palestinian Territory 3
PT - Portogallo 3
RO - Romania 3
SK - Slovacchia (Repubblica Slovacca) 3
TT - Trinidad e Tobago 3
AP - ???statistics.table.value.countryCode.AP??? 2
CR - Costa Rica 2
EE - Estonia 2
GE - Georgia 2
GY - Guiana 2
HR - Croazia 2
NI - Nicaragua 2
PA - Panama 2
QA - Qatar 2
RS - Serbia 2
SN - Senegal 2
TM - Turkmenistan 2
XK - ???statistics.table.value.countryCode.XK??? 2
YE - Yemen 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AD - Andorra 1
Totale 36.530
Salva come PNG Salva come JPEG
Città #
Moscow 3.994
Dublin 1.949
Jacksonville 1.710
Hong Kong 1.498
Santa Clara 1.346
Singapore 1.315
San Jose 864
Chandler 756
Ashburn 385
Princeton 358
Medford 325
Ho Chi Minh City 273
Seoul 257
Bremen 225
Hefei 211
Hanoi 201
Roxbury 188
Boardman 182
San Mateo 157
Beijing 155
The Dalles 149
Bengaluru 139
Wilmington 139
Ann Arbor 102
Woodbridge 86
Cambridge 77
São Paulo 72
Des Moines 71
Dallas 65
Naples 64
Da Nang 59
Düsseldorf 49
New York 49
Caserta 42
Haiphong 42
Rio de Janeiro 38
Los Angeles 34
Munich 34
Norwalk 34
Orem 34
Rome 34
Shanghai 33
Jinan 32
Nanjing 25
Brussels 23
Curitiba 23
Hải Dương 23
Biên Hòa 22
Guangzhou 22
Brasília 21
Milan 20
Tashkent 20
Falkenstein 19
Zhengzhou 19
Belo Horizonte 18
Changsha 18
Guarulhos 18
Hebei 18
Napoli 18
Nuremberg 17
Mountain View 16
Porto Alegre 16
San Potito Sannitico 16
Shenyang 16
Campinas 15
Houston 15
Redwood City 15
Salvador 15
San Marcellino 15
Turku 15
Dhaka 14
Frankfurt am Main 14
Baghdad 13
Bari 13
Goiânia 13
London 13
Osasco 13
Shenzhen 13
Auburn Hills 12
Haikou 12
Phoenix 12
Atlanta 11
Bắc Ninh 11
Canoas 11
Council Bluffs 11
Dearborn 11
Guayaquil 11
Hangzhou 11
Ninh Bình 11
Sorocaba 11
Tokyo 11
Caxias do Sul 10
Lima 10
Manaus 10
Mexico City 10
Thái Bình 10
Tianjin 10
Alvignano 9
Bauru 9
Brooklyn 9
Totale 18.664
Salva come PNG Salva come JPEG
Nome #
Farmaci dell’Apparato Respiratorio: Regolazione del tono broncomotore. 397
Sistema purinergico. 352
“COPDCoRi: applicazione non invasiva per la stima e la previsione del rischio di patologia coronarica nei pazienti affetti da broncopneumopatia cronica ostruttiva (BPCO)”. 179
Effects of chronic administration of β-blockers on airway responsiveness in a murine model of heart failure. 178
Antiflammins suppress the A23187- and arachidonic acid-dependent chloride secretion in rabbit distal colonic mucosa 176
Aclidinium bromide inhalation powder for the long-term, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease including chronic bronchitis and emphysema 170
10. Aclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease. 168
Amminoacidi eccitatori e regolazione centrale della funzione cardiovascolare: contributi sperimentali. 164
Brain natriuretic peptide : much more than a biomarker 159
ACE2: The Major Cell Entry Receptor for SARS-CoV-2 159
Effects of chronic treatment with the new ultra-long-acting β2 -adrenoceptor agonist indacaterol alone or in combination with the β1 -adrenoceptor blocker metoprolol on cardiac remodelling. 154
Severe respiratory SARS-CoV2 infection: Does ACE2 receptor matter? 151
Effect of hyperbaric oxygen therapy in experimental subcutaneous and pulmonary infections due to Pseudomonas aeruginosa 150
A comparison of sensory nerve function in human, guinea-pig, rabbit and marmoset airways 147
1. New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol. 146
Assessing the viability of long-acting β(2)-agonists in paediatric asthma patients: a pharmacokinetic/pharmacodynamic perspective. 144
Calcium dependence of the evoked arginine vasopressin release by electrical stimulation and by L-glutamate 143
Acute effects of higher than customary doses of salmeterol and salbutamol in patients with acute exacerbation of COPD. 143
Sirtuins and Cellular Senescence in Patients with Idiopathic Pulmonary Fibrosis and Systemic Autoimmune Disorders 142
A single high dose of formoterol is as effective as the same dose administered in a cumulative manner in patients with acute exacerbation of COPD 142
Characterization of adenosine receptors involved in adenosine-induced bronchoconstriction in allergic rabbits 140
A comparison of the bronchodilating effects of salmeterol, salbutamol and ipratropium bromide in patients with chronic obstructive pulmonary disease 139
A combination with clinical recommended dosages of salmeterol and ipratropium is not more effective than salmeterol alone in patients with chronic obstructive pulmonary disease 136
Aclidinium bromide for the treatment of chronic obstructive pulmonary disease. 136
An update on the currently available and emerging synthetic pharmacotherapy for uncontrolled asthma 134
Farmaci del sistema cardiovascolare, del sangue e del rene 134
Protein Prenylation Contributes to the Effects of LPS on EFS-Induced Responses in Human Isolated Bronchi 134
Excitatory amino acids and cardiovascular apparatus: experimental studies on conscious rats with L-glutamate, N-methyl-D-aspartate, kainate and quisqualate 133
Effects of hyperbaric oxygen exposure on non-adrenergic non-cholinergic responses of rat trachea 133
5-HT modifiers as a potential treatment of asthma 133
A review of the pharmacokinetics of M3 muscarinic receptor antagonists used for the treatment of asthma 132
A comparison of bronchodilating effects of salmeterol and oxitropium bromide in stable chronic obstructive pulmonary disease 131
Animal models of chronic obstructive pulmonary disease and their role in drug discovery and development: a critical review 131
The anti-proliferative effects of adiponectin on human lung adenocarcinoma A549 cells and oxidative stress involvement 130
Contribution of sensory nerves to LPS-induced hyperresponsiveness of human isolated bronchi. 129
. Brain natriuretic peptide modulates calcium homeostasis and epidermal growth factor receptor gene signalling in asthmatic airways smooth muscle cells. 127
K+ channels and guinea-pig trachea: a possible functional modulation by GABAB receptors 127
Pulmonary penetration of dirithromycin in patients suffering from acute exacerbation of chronic bronchitis 126
Role of 5-hydroxytryptamine in mediating adenosine-induced airway contraction 125
[The therapeutic prospects of ischemic cardiopathy] 125
Research on heterocyclic compounds. XIV - Imidazothiazole and imidazobenzothiazole derivatives: synthesis and antiinflammatory activity 124
A safety comparison of LABA+LAMA vs LABA+ICS combination therapy for COPD 124
Chronic obstructive pulmonary disease and coronary disease: COPDCoRi, a simple and effective algorithm for predicting the risk of coronary artery disease in COPD patients. 123
Effects of RO 5-4864 and PK 11195 on guinea pig trachea 122
Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways. 121
N-acetylcysteine in COPD may be beneficial, but for whom? 121
Effects of in vitro 5-HT1 receptor activation in guinea pig trachea 120
Evidence of muscarinic receptor subtypes in airway smooth muscle of normal volunteers and of chronic obstructive pulmonary disease patients 120
Flomoxef, a new oxacephem antibiotic, does not cause hemostatic defects 120
A systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD 120
Ions and intracellular mechanisms involved in the effects of L-glutamate on arginine vasopressin release: in vitro researches on rat neurohypophysis 119
N-Acetylcysteine protects human bronchi by modulating the release of neurokinin A in an ex vivo model of COPD exacerbation. 118
Immune checkpoint inhibitors: a new landscape for extensive stage small cell lung cancer treatment 118
The additive effect of theophylline on a combination of formoterol and tiotropium in stable COPD: a pilot study 117
Prenatal and postnatal vanadium exposure in rats: effect on vasomotor reactivity development of pups 117
A potential role of triple therapy for asthma patients 117
Umeclidinium bromide + vilanterol for the treatment of chronic obstructive pulmonary disease. 116
Brain Natriuretic Peptide Protects Against Hyperreactivity of Human Asthmatic Airway Smooth Muscle via an Epithelial Cell Dependent Mechanism. 116
Drug-Drug Interactions and Synergy: From Pharmacological Models to Clinical Application 115
Functional role of nitric oxide in guinea pig tracheal epithelium 115
Intraulmonary penetration of antimicrobials and implications in the treatment of lower respiratory tract infections. 115
A long-term clinical trial on the efficacy and safety profile of doxofylline in Asthma: The LESDA study 115
Treating systemic effects of COPD. 114
Prenatal and postnatal antimony exposure in rats: effect on vasomotor reactivity development of pups 114
Treatment of COPD: moving beyond the lungs. 114
Adding a LAMA to ICS/LABA therapy: a meta-analysis of triple therapy in COPD 114
Terapie per i disordini labirintici: effetti e riflessi sulla pressione arteriosa 113
Pharmacokinetic/pharmacodynamic drug evaluation of benralizumab for the treatment of asthma. 113
Evidence for non-adrenergic non-cholinergic contractile responses in bovine and swine trachea 113
characterization of the Pharmacological interaction between aclidinium bromide and formoterol fumarate on human isolated bronchi. 112
The burden of obesity in asthma and COPD: Role of adiponectin 111
Advances in the Pharmacological Management of Pediatric Acute Respiratory Distress Syndrome 111
Pulmonary concentrations of dirithromycin and erythromycin during acute exacerbation of mild chronic obstructive pulmonary disease 110
Translational Study Searching for Synergy between Glycopyrronium and Indacaterol. 110
Farmaci per il trattamento della cardiopatia ischemica. 110
Farmaci per il trattamento delle aritmie cardiache. 110
Bioavailability of timolol and aceclidine after ocular instillation in the rabbit 109
I farmaci del sistema nervoso centrale 109
Safety Considerations with Dual Bronchodilator Therapy in COPD: An Update 109
Pharmacological treatment and current controversies in COPD 108
Tremor and β(2)-adrenergic agents: is it a real clinical problem? 108
Current pharmacotherapeutic options for pediatric lower respiratory tract infections with a focus on antimicrobial agents 107
Possible functional modulation by acetylcholine of nitric oxide on guinea pig isolated trachea 107
Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis 107
Pharmacological Characterization of Adenosine Receptors on Isolated Human Bronchi 106
Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary disease. 106
Role of 5-HT2 receptor subtypes in mediating adenosine-induced airway contraction 106
Bronchodilator response to formoterol Turbuhaler in patients with COPD under regular treatment with formoterol Turbuhaler 106
Nitric oxide regulatory role in sensitized guinea pig trachea 106
Theophylline in the inhibition of angiotensin-converting enzyme inhibitor-induced cough 105
Impact of biologics on lung hyperinflation in patients with severe asthma 104
Ondansetron, an antagonist of 5-HT3 receptors, in the treatment of antineoplastic drug-induced nausea and vomiting in children 104
Addition of an extra dose of salmeterol Diskus to conventional dose of salmeterol Diskus in patients with COPD 104
Serum digoxin levels after concomitant ticarcillin and clavulanic acid administration 103
Pulmonary disposition of lomefloxacin in patients with acute exacerbation of chronic obstructive pulmonary disease. A multiple-dose study 103
Bronchodilator therapy for chronic cough 103
A comprehensive overview of investigational elastase inhibitors for the treatment of acute respiratory distress syndrome 102
Use of indacaterol for the treatment of COPD: a pharmacokinetic evaluation. 102
Nitric oxide and airways. 102
Bacterial lysates as a potentially effective approach in preventing acute exacerbation of COPD. 102
Totale 12.909
Salva come PNG Salva come JPEG
Categoria #
all - tutte 125.431
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 125.431
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021611 0 0 0 0 0 0 0 0 0 289 260 62
2021/20221.931 167 15 27 42 686 7 25 47 59 70 185 601
2022/20233.439 410 47 35 234 440 248 7 178 1.690 17 53 80
2023/20241.391 103 34 35 137 549 59 36 33 14 21 85 285
2024/20255.482 34 33 57 154 871 614 551 446 656 1.408 394 264
2025/202618.779 845 799 1.033 1.254 1.275 10.660 1.152 704 770 287 0 0
Totale 36.943